Clinical trial
Human Papillomavirus Vaccine Immunogenicity and Safety Trial in Young Adult…
NCT00359619 · GlaxoSmithKline, Industry · Completed
Key facts
| NCT number | NCT00359619 |
|---|---|
| Title | Human Papillomavirus Vaccine Immunogenicity and Safety Trial in Young Adult Women With GSK Biologicals Novel HPV Vaccine |
| Official title | A Long-term, Follow-up of the Immunogenicity and Safety of GlaxoSmithKline Biologicals' Novel HPV Vaccine in Healthy Female Subjects Vaccinated in the Primary Study |
| Lead sponsor | GlaxoSmithKline, Industry |
| Status | Completed |
| Phase | Phase 2 |
| Study type | Interventional |
| Conditions | Infections, Papillomavirus, Papillomavirus Vaccines |
| Intervention type | Biological |
| Interventions | CervarixTM, HPV investigational vaccine GSK568893A, different formulations |
| Enrollment | 383 |
| Start date | Sep 12, 2006 |
| Primary completion | Jan 30, 2007 |
| Completion | Jan 30, 2007 |
| First posted | Aug 2, 2006 |
| Last update posted | Jan 2, 2020 |
| Countries | Belgium, United States |
At a glance
- 10–99 Study sites
- Yes Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: